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Despite  tremendous  improvement  in  i t s  c l in ica l 
management, lung cancer is still the leading cause of cancer 
related death worldwide (1). It is usually diagnosed at 
advanced stage and only a minority of patients presents an 
early and potentially curable disease. However, with positive 
results of low-dose computed tomography (CT) screening 
in the high-risk population and with the improvement 
of diagnostic techniques, early diagnoses can hopefully 
increase in the near future (2). Therefore, defining the best 
curative treatment approach for this disease setting is of 
crucial relevance. 
Liang and colleagues focused their attention on the 
subset of epidermal growth factor receptor (EGFR) 
positive patients cured with surgical resection and drew 
up a consensus on postoperative adjuvant targeted therapy 
management (3). As well known, EGFR mutations occur 
in the 10–15% of Caucasian patients and up to the 40% 
of Asian ones (4). EGFR testing is recommended in all 
patients with advanced non-squamous non-small cell 
lung cancer (NSCLC), but also in patients with pure 
squamous histology, especially if young and/or non-
smokers. EGFR tyrosine kinase inhibitors (TKIs) represent 
the recommended first-line treatment in patients with 
advanced NSCLC bearing classic mutations (i.e., exon 
19 in-frame deletions and exon 21-point mutations) (5). 
Several randomized trials have demonstrated, indeed, the 
superiority of oral treatment with EGFR TKIs compared to 
standard platinum-based chemotherapy for this subgroup 
of patients (4). In the consensus document, authors stated 
that also NSCLC patients who have undergone a radical 
resection need EGFR mutation profiling and that EGFR-
TKIs can replace chemotherapy in patients candidate to 
adjuvant therapy after surgery, above all in patients who 
would probably not tolerate chemotherapy treatment, 
defining “at least 2 years” as the optimal treatment duration. 
In absence of direct comparisons, the reported adjuvant 
treatments are heterogeneous: chemotherapy, EGFR-TKI, 
chemotherapy plus EGFR-TKI (3).  
Actually, several studies have evaluated the possibility 
of biological drugs as adjuvant therapy and the results 
are quite conflicting. What is clear is that, even in early 
stages, adjuvant treatment with EGFR TKIs could be 
effective only in those patients whose tumor expresses an 
EGFR activating mutation. Two are the phase III studies 
showing that erlotinib for 2 years or gefitinib for 1 year 
did not improve disease-free survival (DFS) [erlotinib: 
hazard ratio (HR) 0.90, 95% confidence interval (CI): 
0.74–1.10, P=0.32; gefitinib: HR 1.28; 95% CI: 0.92–1.76; 
P=0.14] or overall survival (OS) (erlotinib: HR 1.13, 
95% CI: 0.88–1.44, P=0.33; gefitinib: HR 1.24; 95% 
CI: 0.90–1.71; P=0.18) compared to placebo in radically 
resected NSCLC patients (stage IB–IIIA) and not selected 
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for EGFR mutations (6,7). However, also in a molecular 
selected population, advantages seem limited only to DFS, 
which is a clear surrogate endpoint of efficacy especially 
in the adjuvant setting, and OS data remain immature. In 
two randomized trials, one phase II (the EVAN trial) and 
one phase III (the ADJUVANT study) conducted in Asian 
patients with EGFR-positive radically operated stage II–III 
NSCLC, a benefit in DFS was observed with erlotinib for 
2 years (percentage of free disease patients: 81.4%, 95% CI: 
69.6–93.1% versus 44.6%, 95% CI: 26.9–62.4%; P=0.0007) 
and with gefitinib for 2 years (28.7 versus 18.0 months, HR 
0.60; 95% CI, 0.42–0.87, P=0.005), when compared to the 
adjuvant chemotherapy with cisplatin-vinorelbine (8,9). In 
both studies, the OS advantage could not be demonstrated. 
A phase II study conducted in patients with surgical-
treated high-risk IIIA stage EGFR+ NSCLC reported 
an improvement in DFS (HR 0.37; 95% CI: 0.16–0.85; 
P=0.014), in the absence of OS benefit, with gefitinib for 
6 months versus observation alone after adjuvant 
chemotherapy (10). Another phase II study, performed in 
resected patients with NSCLC (stage IB–IIIA) and activating 
EGFR mutation, did not report a significant increase in DFS 
with icotinib for 4–8 months versus the only observation after 
platinum-based adjuvant chemotherapy (11). Furthermore, 
Pennell et al. published a single-arm phase II trial of 
adjuvant erlotinib after surgery and consolidative chemo/
radiotherapy in stage IA–IIIA NSCLC patients, reporting a 
2-year DFS of 88% (no median DFS or OS reported) (12). 
A recent metanalysis confirmed that adjuvant TKIs 
reduce the risk of recurrence in EGFR mutant NSCLC 
patients without benefit in OS (13). Trials with OS as 
primary endpoint such as the ALCHEMIST-EGFR 
(NCT02193282) study, in which EGFR+ NSCLC patients 
are randomized to 2-year erlotinib or placebo after adjuvant 
chemotherapy, are still ongoing (14). The absence of OS 
improvement is a critical aspect in evaluating the benefit 
of a treatment with adjuvant intent. Pignon et al. in 2008 
published the Lung Adjuvant Cisplatin Evaluation (LACE) 
meta-analysis that included individual data from 5 phase 
III studies, which randomized patients with stage I–IIIA 
NSCLC radically operated to receive cisplatin-based 
chemotherapy versus observation only (15). This meta-
analysis reports a HR of 0.89 (95% CI: 0.82–0.96, P=0.005), 
which corresponds to an absolute 5-year survival benefit 
of 5.4%, in favor of adjuvant chemotherapy. Thus, in the 
absence of improved OS data for adjuvant EGFR TKIs 
compared to chemotherapy, at present, it seems reasonable 
to do not recommend routine molecular testing in the 
adjuvant setting, unless functional to the inclusion in clinical 
trials. Targeted therapies, with or without chemotherapy, 
cannot be recommended in the adjuvant treatment of 
NSCLC outside of experimental protocols (5). 
Another element of concern for strong positive 
recommendations for adjuvant TKIs is related to the 
heterogeneity of trials, design, selected population and 
duration of treatment. The definition of a timeframe 
of 2-year treatment after surgical resection, as reported 
by authors, seems quite empiric. Thus, even if targeted 
therapies are usually more tolerated than chemotherapy, is 
important to underline that can be characterized by adverse 
events such as skin, gastrointestinal toxicities or fatigue for 
the entire duration of treatment (2 years versus 3 months 
of chemotherapy), potentially requiring dose reduction, 
treatment interruption and impairing patient compliance: 
actually in clinical trials up to one-third of patients did not 
complete the two years pre-planned treatment. Also, in the 
case of more tolerable treatment, as 3rd generation TKI, 
the risk of relevant toxicities exists (e.g., lung interstitial 
disease), although low. 
In the consensus document, authors propose to 
follow-up EGFR+ patients with annual brain magnetic 
resonance imaging (MRI) and bone scan, additionally to 
conventional CT, because of the higher risk of recurrence 
for this patients’ subset (3). The European Society 
for Medical Oncology (ESMO) recommend the brain 
staging with MRI for all patients in stage III (16). For 
the other disease stages international recommendations 
are quite heterogeneous. The National Comprehensive 
Cancer Network (NCCN) recommends brain MRI 
in all patients with early or locally advanced NSCLC, 
excluding stage IA (5); the National Institute for Health 
and Care Excellence (NICE) recommends brain CT in 
stage II and brain MRI for people with stage III NSCLC 
who are having a treatment with curative intent (17); 
on the other hand the American College of Chest Physicians 
(ACCP) limits the indication to stage III and IV and in 
case of symptomatic patients (18). As well-known, NSCLC 
patients with EGFR mutations appear to have a higher 
incidence (50–60%) of brain metastasis (19), therefore 
appears reasonable to implement brain-imaging follow up 
for their early detection. However, considering the absence 
of improvements in OS, solid prospective data are needed 
before recommending an intensive follow up strategy. Bone 
scintigraphy is considered optional in the imaging work-
up for diagnosis and staging by ESMO guidelines (16) and 
current data are still weak to implement its execution in case 
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of asymptomatic patients. 
Which should be the hypothetical best TKI to be used in 
the adjuvant setting is another element of uncertainty. Liang 
et al. in the consensus emphasize the role of osimertinib 
as the best option; nevertheless, available data of 3rd 
generation TKI usage in EGFR+ patients are, currently, 
limited to stage IV patients with EGFR mutations (exon 
19 deletion of L858R allele), for whom is preferable in 
respect to 1st generation TKI, as elucidated in the FLAURA 
trial. Updated OS data reported a gain of 6.8 months of 
survival when osimertinib is administered upfront (HR for 
death, 0.80; 95.05% CI: 0.64–1.00; P=0.046) (20). For these 
reasons is plausible to consider its role at relapse for EGFR+ 
patients initially treated with surgery, but no evidence exists 
preferring the administration of osimertinib, rather than 
other EGFR TKI, in the adjuvant setting. The results of 
ongoing trial ADAURA (NCT02511106), expected in the 
third quarter of 2021, will give us relevant insights about 
the role of adjuvant osimertinib in terms of DFS—as 
primary endpoint—OS and health-related quality of life, as 
secondary endpoints (21).
Furthermore, unfortunately, we still ignore the precise 
biological mechanism at the basis of adjuvant EGFR 
targeting. We cannot exclude flare reactions with TKIs 
suspension, potentially caused by the reactivation of the 
microscopic disease that targeted therapies are unable to 
completely eradicate (22). And, more clinically relevant, 
we have no tools to forecast the biological evolution of 
EGFR+ neoplastic cells under drug pressure. If the rate 
of T790M emergence during adjuvant treatment with 1st 
generation TKI seems low (12), we do not have any ideas 
whether treatment with more potent TKI might spur the 
development of more aggressive clones, difficult to be 
treated after; recent data shed light on relevant alternative 
mechanisms of resistance, such as histotype transition and 
off-target alterations that should be taken into account 
when an adjuvant treatment is selected (23).
Finally, the position paper on the postoperative 
management of EGFR-mutated NSCLC patients highlights 
a relevant aspect in thoracic oncology, adjuvant targeted 
treatments for EGFR+ patients, which will acquire even 
more significance in the next future of improved screening 
and early detection. However, the only availability of PFS 
data and the need of larger studies in not-Asiatic population 
put emphasis on the importance of having more solid and 
numerous data before recommending the use of EGFR-
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